Kotak Invests ₹940 Crore in Neuberg Diagnostics to Drive Expansion and IPO Preparation

NICE Recommends Olaparib for BRCA-Mutated Advanced Breast Cancer

SOPHiA GENETICS and Platomics Collaborate to Streamline IVDR Compliance for Clinical Labs

India Unveils Genome Sequencing Data of 10,000 Individuals: A Milestone in Biotechnology Research

Ambry Genetics Advances BRCA2 Variant Classification with CRISPR-Based Study Published in *Nature*

Geneoscopy Secures $105M Series C Funding to Advance Colorectal Cancer Screening

Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

MD Anderson and Myriad Genetics Forge Strategic Alliance to Advance MRD Testing in Cancer Care

Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

China’s NMPA Approves Astellas’ Zolbetuximab for Advanced Gastric and GEJ Cancer

Renovaro to Acquire Predictive Oncology in All-Stock Deal

Portage Biotech Relaunches Subsidiary as Cyncado Therapeutics to Advance Next-Generation Immuno-Oncology Therapies

ADSCC Pioneers Clinical-Grade iPSCs, Advancing Regenerative Medicine in the Middle East

Home
/
update
/
details

QDX and Prelude Therapeutics Announce Collaboration on Innovative Oncology Programs

NextEdge Admin

23 Jul 2024

1 min 57 sec

QDX, a leading computational drug discovery company, has announced a collaboration with Prelude Therapeutics, a clinical-stage precision oncology firm, to target previously undrugged oncology targets.

QDX leverages its advanced quantum mechanical simulation technology, supercomputing, AI, and deep expertise in drug discovery to push the boundaries of computational chemistry and drug development.

Peggy Scherle, PhD, CSO of Prelude, stated, "Computational drug discovery is showing great promise. We are excited to partner with QDX’s talented team, combining their high-performance computing, quantum simulations, and AI to tackle these historically challenging targets."

Loong Wang, Co-Founder and CEO of QDX, expressed, "We are excited to collaborate with Prelude to pioneer new advances in these programs. This partnership exemplifies QDX's commitment to bespoke collaborations across academia and industry, utilizing our cutting-edge quantum technology, supercomputing, and AI systems."

Kelvin Neu, MD, Co-Founder and Chair of QDX, added, "Prelude's accomplished biology and chemistry teams have developed a productive pipeline of small molecules targeting crucial and challenging oncology targets. QDX has built a powerful platform by integrating complementary disciplines, guided by practical drug discovery needs, especially in traditionally difficult areas. We are honored to support Prelude on these targets and anticipate a fruitful collaboration."